investorscraft@gmail.com

Intrinsic value of Bristol Myers Squibb Company (BMY)

Previous Close$71.52
Intrinsic Value
Upside potential
Previous Close
$71.52
Use floor (the cash flow based valuation has rendered a result, which is lower than an estimated minimum value derived from the company’s balance sheet analysis)

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh41.81 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration agreement with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc.; and a discovery collaboration with Insitro, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %9.1NaN
Revenue, $46385NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m38287NaN
Operating income, $m8098NaN
EBITDA, $m18784NaN
Interest expense (income), $mNaN
Earnings before tax, $m8078NaN
Tax expense, $m1084NaN
Net income, $m6994NaN

BALANCE SHEET

Cash and short-term investments, $m17361NaN
Total assets, $m109314NaN
Adjusted assets (=assets-cash), $m91953NaN
Average production assets, $m75266NaN
Working capital, $m11394NaN
Total debt, $m45596NaN
Total liabilities, $m73368NaN
Total equity, $m35946NaN
Debt-to-equity ratio1.268NaN
Adjusted equity ratio0.258NaN

CASH FLOW

Net income, $m6994NaN
Depreciation, amort., depletion, $m10686NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m16207NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-973NaN
Free cash flow, $m17180NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m11394
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount